Naples

• A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting
  2024-516440-25-00 1 2025-02-06 KRAS G12D-mutant solid tumors.
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• “A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br … Recruiting
  2024-519514-31-00 4 2025-01-31 metastatic triple-negative PD-L1 positive breast cancer
• A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an … Recruiting
  2024-512900-20-00 7 2025-01-30 Non-muscle invasive bladder cancer (NMIBC)
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line … Recruiting
  2024-511945-20-00 4 2025-01-24 patients affected by small cell lung cancer (SCLC)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum … Recruiting
  2023-503675-24-00 5 2025-01-17 Triple-negative Breast Cancer
• A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca … Recruiting
  2024-511775-15-00 4 2025-01-17 Immune system diseases
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M … Recruiting
  2024-516841-38-00 4 2025-01-09 recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 Recurrent ovarian cancer
• Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in p … Recruiting
  2024-513303-14-00 1 2025-01-08 Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) charact
• A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type … Recruiting
  2024-519481-44-00 4 2025-01-08 colorectal metastatic cancer
• A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR … Recruiting
  2023-510109-16-00 4 2025-01-06 Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
• PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting
  2024-516450-21-00 6 2024-12-31 metastatic or locally advanced urothelial cancer
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi … Recruiting
  2024-514420-16-00 4 2024-12-18 RAS/BRAF wild-type metastatic colorectal cancer
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject … Recruiting
  2024-513860-25-00 9 2024-12-10 Ovarian Neoplasms
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap … Recruiting
  2024-512053-24-00 4 2024-12-05 recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic can … Recruiting
  2024-519067-17-00 4 2024-12-02 Locally Advanced Pancreatic Cancer
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav

Showing 409–432 of 1,177 trials